MacDonald Kelly, SVP and CFO, has exclusively traded shares of Dynavax Technologies (DVAX) over the course of 29 reported transactions, all of which were sales totaling $752,288.85. The most significant disposals occurred on December 24, 2025, when Kelly sold shares worth $555,848.58, followed by earlier transactions on February 13, 2025 ($67,485.42), February 18, 2025 ($64,326.75), and February 10, 2025 ($26,360.40). The remaining transactions, primarily coded as derivative dispositions (D), awards (A), or other adjustments (U), did not involve monetary value.
Kelly’s trading history shows a clear divestment pattern, with no recorded purchases in DVAX. The bulk of the realized sales took place in late 2025, with the largest single transaction occurring just before the year-end. While recent filings from February 2026 indicate continued adjustments to holdings, these were non-monetary, suggesting administrative updates rather than new sales. The absence of buy activity and the concentration of sales in a single biotech stock may reflect portfolio rebalancing or personal financial planning, though the filings provide no explicit rationale. The transactions underscore a consistent reduction in Kelly’s stake in Dynavax over the observed period.
AI-assisted summary